This phase III, randomized, placebo-controlled, double-blind study determined whether motesanib improved progression-free survival (PFS) compared with placebo in combination with paclitaxel and carboplatin (P/C) in East Asian patients with stage IV/recurrent nonsquamous non-small-cell lung cancer.
INTRODUCTION
Motesanib, a selective, oral, small-molecule inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit receptor, 1 has demonstrated antitumor activity as monotherapy [2] [3] [4] and in combination with chemotherapy in advanced solid tumors. 5, 6 A phase II, randomized, open-label study in chemotherapy-naïve patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) indicated that the efficacy of motesanib is comparable with the anti-VEGF-A monoclonal antibody bevacizumab when both therapies are used in combination with paclitaxel and carboplatin (P/C). 5 In the phase III, randomized, placebocontrolled, double-blind Motesanib NSCLC Efficacy and Tolerability (MONET1) study, motesanib plus P/C did not significantly improve overall survival (OS) versus placebo plus P/C in patients with advanced nonsquamous NSCLC or in a subset of patients with adenocarcinoma 6 ; however, a preplanned exploratory subgroup analysis of 227 East Asian patients in this study demonstrated a median OS of 20.9 months in the motesanib plus P/C arm and 14.5 months in the placebo plus P/C arm (P = .0223); median progression-free survival (PFS) was 7.0 and 5.3 months, respectively (P , .001), and the objective response rate (ORR) was 62% and 27%, respectively (P , .001). 7 Mounting evidence shows differences between Asian and white patients with lung cancer in terms of epidemiology, etiology, treatment outcomes, and toxicities. 8 A higher incidence of epidermal growth factor receptor (EGFR) mutations has been reported in Asian versus non-Asian patients with NSCLC (32% to 51.4% v 6%). [8] [9] [10] Improved efficacy and higher levels of toxicity with P/C also have been reported for patients with NSCLC in Japan versus the United States, which may be explained by population-related pharmacogenomics.
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On the basis of the MONET1 Asian subgroup analysis 7 and successful exploratory modeling and simulations that were based on MONET1 data, 12 the primary objective of the current phase III, randomized, placebo-controlled, double-blind MONET-A study was to determine whether motesanib plus P/C improved PFS versus placebo plus P/C in East Asian patients with advanced/recurrent nonsquamous NSCLC.
PATIENTS AND METHODS

Patients
Patients age $ 18 years with histologically or cytologically confirmed stage IV/recurrent nonsquamous NSCLC were eligible. Other inclusion criteria were measurable or nonmeasurable lesion per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1); Eastern Cooperative Oncology Group performance status 0 or 1; life expectancy $ 3 months; and adequate renal, hepatic, coagulation, and hematologic function. Patients with antigen-negative hepatitis B who were hepatitis B antibody positive were eligible. Key exclusion criteria were adenosquamous histology or an unclear histology subtype (. 10% squamous cells); symptomatic CNS metastases (clinically stable patients with asymptomatic brain metastases were eligible if definitive therapy had been administered, and the patient was not receiving corticosteroids for $ 2 weeks before random assignment); history of pulmonary hemorrhage or gross hemoptysis (approximately $ 3 mL of brightred blood) within 6 months of random assignment; prior chemotherapy, including adjuvant chemotherapy within 1 year of random assignment; prior targeted therapy; major surgery within 28 days or anticoagulation therapy within 7 days of random assignment; uncontrolled hypertension; and arterial or venous thrombosis within 12 months or bleeding diathesis or bleeding within 14 days of random assignment. The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice, and study procedures were approved by the institutional review board at each site. All patients provided written informed consent.
Study Design and Treatments
This phase III, randomized, placebo-controlled, double-blind study was conducted at 52 sites in Japan (n = 24), Korea (n = 17), Taiwan (n = 10), and Hong Kong (n = 1) between July 2012 and March 2015. Patients were randomly assigned (1:1) by interactive Web response system to either once-daily oral motesanib 125 mg or matching placebo; all patients also received paclitaxel 200 mg/m 2 IV and carboplatin area under the concentration-time curve 6 mg/mL $ min IV on day 1 of each 3-week cycle for up to six cycles. Random assignment was stratified by EGFR status (mutant v wild type or unknown), region (Japan v non-Japan), and weight loss in the 6 months before assignment (, 5% v $ 5%). Patients who discontinued P/C before completing or as a result of the protocol-specified six cycles could continue to receive motesanib or placebo monotherapy until disease progression, unacceptable toxicity, withdrawal of consent, or death.
The primary end point was investigator-assessed PFS, which was defined as the time from random assignment to the first objective tumor progression or death as a result of any cause. The key secondary end point was OS, which was defined as the time from random assignment to death. Other secondary end points were ORR by investigator, time to tumor response, duration of response (DOR), and incidence of adverse events (AEs).
Assessments
Tumor response was assessed by computed tomography and magnetic resonance imaging scans every 6 6 1 weeks by the investigators and by an independent imaging assessment committee per RECIST 1.1 until progressive disease. Safety was assessed through 30 days after the last dose. AEs were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0). Interim analyses of safety were conducted by the data monitoring committee after 50 and 150 patients had been randomly assigned and had completed one or more cycles of study treatment. An additional exclusion criterion for patients with interstitial lung disease on computed tomography scan was added, but interim analyses are not reported because no recommendations were made to modify or stop treatment or to suspend random assignment.
Statistical Analysis
A sample size of 400 patients (200 per arm) was determined to provide 90% power (overall one-sided 2.5% significance level) to detect a hypothesized PFS hazard ratio (HR) of 0.67 and an increase in median PFS from 5.3 months in the placebo plus P/C arm to 7.9 months in the motesanib plus P/C arm after the occurrence of a minimum of 260 PFS events. An interim analysis of OS was planned at the same time as this primary analysis but was conditional on demonstrating a significant improvement in PFS.
PFS and OS were analyzed in all randomly assigned patients. Safety was analyzed in all patients who received one or more doses of motesanib or placebo. ORR was analyzed in all patients with one or more unidimensionally measurable lesion at baseline per RECIST 1.1. PFS, OS, and DOR distributions were estimated by using the Kaplan-Meier method. The primary end point of PFS and key secondary end point of OS were compared between arms by using log-rank tests stratified by randomization factors; stratified Cox proportional hazards (PH) regression models were used to define HRs. Unstratified Cox PH regression models with descriptive P values were used for the preplanned, exploratory PFS and OS subgroup analyses; no adjustments were made for multiple comparisons. The following baseline covariates were used to examine selected efficacy and safety end points in subgroup or multivariable analyses: the three stratification factors; histology (adenocarcinoma v nonadenocarcinoma); disease status at enrollment (initial v recurrent); prior adjuvant chemotherapy (yes v no); sex (male v female); prior radiation therapy (yes v no); brain metastases (yes v no); age at enrollment (, 65 v $ 65 years); smoking history ($ 100 v , 100 cigarettes in lifetime); and baseline Eastern Cooperative Oncology Group performance status (0 v 1). A stratified Cochran-Mantel-Haenszel test was used for the primary comparison of ORR. Descriptive statistics are presented for safety data.
RESULTS
Patients
In total, 401 patients were randomly assigned to motesanib plus P/C (n = 197) or placebo plus P/C (n = 204). Demographic characteristics were similar between arms and representative of the population under study (Table 1) . At study entry, the overall median age was 65.0 years (range, 25 to 80 years), 71.8% of patients were male, and 70.6% were enrolled in Japan; the majority had previously smoked (59.6%) or were current smokers (12.2%) and had wild-type or unknown-type EGFR (79.3%). Except for one patient in the motesanib plus P/C arm who did not receive motesanib or P/C and one patient in the placebo plus P/C arm who did not receive carboplatin, all patients received concomitant P/C. At the time of the PFS primary analysis, 165 patients (83.8%) in the motesanib plus P/C arm and 166 (81.4%) in the placebo plus P/C arm had discontinued motesanib or placebo (Fig 1) .
Treatment Exposure
By the data cutoff date of September 30, 2014, median daily doses of motesanib and placebo were 125 mg. Patients received motesanib for a median of 4.5 months (range, 0.1 to 24.6 months) and placebo for a median of 4.3 months (range, 0.03 to 23.7 months). P/C was administered for a median of four cycles (range, one to six cycles) in the motesanib plus P/C arm and five cycles (range, one to six cycles) in the placebo plus P/C arm. In the maintenance (monotherapy) phase, patients received motesanib for a median of 2.8 months (range, 0.03 to 21.0 months) and placebo for 2.1 months (range, 0.03 to 19.1 months).
Efficacy
PFS by investigator: Primary end point. The data cutoff date for the PFS primary analysis was September 30, 2014; unless otherwise stated, efficacy and safety data are reported from this primary analysis.
At this cutoff, 143 patients (72.6%) in the motesanib plus P/C arm and 152 (74.5%) in the placebo plus P/C arm had experienced a PFS event (death or disease progression). After a median follow-up of 10.3 months (range, 0.5 to 25.5 months) for the motesanib plus P/C arm and 10.1 months (range, 0.5 to 26.7 months) for the placebo plus P/C arm, median PFS was 6.1 months (95% CI, 5.65 to 7.13 months) v 5.6 months (95% CI, 5.36 to 5.91 months) for motesanib plus P/C and placebo plus P/C, respectively (stratified log-rank test P = .0825; stratified Cox PH regression model HR, 0.81; 95% CI, 0.64 to 1.03; P = .0820; Fig 2A) . The hypothesized improvement in PFS was not demonstrated, and on the basis of this result plus data on OS, other secondary efficacy end points, and the safety profile, the study was terminated (final data cutoff, March 31, 2015) .
Prespecified subgroup analyses showed a trend toward a consistent PFS benefit with motesanib plus P/C across subgroups except for patients with recurrent disease at enrollment and patients who had undergone prior adjuvant therapy (Fig 2B) . Of note, a PFS benefit (HR , 1 and 95% CI that did not overlap unity) was observed for patients with mutant-type EGFR (HR, 0.57 by unstratified Cox PH regression model; 95% CI, 0.33 to 0.98; P = .0413), $ 5% weight loss before random assignment (HR, 0.64; 95% CI, 0.43 to 0.96; P = .0299), no prior adjuvant therapy (HR, 0.77; 95% CI, 0.61 to 0.97; P = .0261), and prior radiation therapy (HR, 0.58; 95% CI, 0.34 to 0.98; P = .0418). 1 (0.6, 1.6) 1 (0.6, 1.4) 1 (0.6, 1.5)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; P/C, paclitaxel and carboplatin. *Data missing for one patient in the placebo + P/C arm. †Data shown from clinical report forms rather than from interactive Web response system.
jco.org OS: Key secondary end point. Interim analysis of OS was conditional on demonstrating a significant improvement in PFS. Formal statistical testing of OS and other secondary end points, therefore, was not performed; results are descriptive and not intended for inferential purposes.
At the time of the PFS primary analysis, 56 patients (28.4%) in the motesanib plus P/C arm experienced an event (death) versus 62 (30.4%) in the placebo plus P/C arm. The estimated median OS was not reached (NR; 95% CI, 18.33 months to NR) in the motesanib plus P/C arm versus 21.6 months (95% CI, 17.48 to NR) in the placebo plus P/C arm (stratified log-rank test P = .5514; stratified Cox PH regression model HR, 0.90; 95% CI, 0.62 to 1.29; P = .5536; Fig 3) . At final data cutoff (March 31, 2015) , 82 patients (41.6%) in the motesanib plus P/C arm experienced an event versus 80 (39.2%) in the placebo plus P/C arm. After a median follow-up of 13.6 months (range, 0.5 to 30.4 months) for the motesanib plus P/C arm and 12.6 months (range, 0.5 to 31.3 months) for the placebo plus P/C arm, the estimated median OS was 22.8 months (95% CI, 18.33 months to NR) and 21.6 months (95% CI, 17.48 months to NR) for motesanib plus P/C and placebo plus P/C, respectively (stratified log-rank test P = .9356; stratified Cox PH regression model HR, 1.01; 95% CI, 0.74 to 1.38; P = .9347). Prespecified subgroup analyses showed a trend toward an OS benefit (HR , 1) in patients with mutant-type EGFR (HR, 0.45 by unstratified Cox PH regression model; 95% CI, 0.14 to 1.47; P = .1863).
Tumor response by investigator. Overall, 193 patients in the motesanib plus P/C arm and 197 in the placebo plus P/C arm had measurable disease. The ORR was 60.1% v 41.6% for the motesanib plus P/C versus placebo plus P/C arms, respectively (difference in rate, 18.5%; 95% CI, 8.21% to 28.74%; P , .001). The median time to tumor response was 1.4 v 1.6 months, and the estimated median DOR was 5.3 v 4.1 months with motesanib plus P/C versus placebo plus P/C, respectively (Table 2) . (n = 31) (n = 165) (n = 84) (n = 63) (n = 10) (n = 5) (n = 2) (n = 1) (n = 0) (n = 0) (n = 69) (n = 123) (n = 69) (n = 123) (n = 3) (n = 193) (n = 97) (n = 67) (n = 10) (n = 6) (n = 9) (n = 2) (n = 0) (n = 2) (n = 71) (n = 125) (n = 71) (n = 125) (n = 38) (n = 166) (n = 125) (n = 28) (n = 6) (n = 2) (n = 3) (n = 1) (n = 1) (n = 0) (n = 87) (n = 106) (n = 87) (n = 105) (n = 4) (n = 200) (n = 147) (n = 30) (n = 6) (n = 5) (n = 7) (n = 1) (n = 1) (n = 3) 
Safety
The safety analysis set consisted of 196 patients who received motesanib plus P/C and 204 who received placebo plus P/C. Overall, the incidence of AEs (100% v 99.5%), motesanib/placebo-related AEs (93.4% v 79.4%), grade $ 3 AEs (86.7% v 67.6%), serious AEs (48% v 32.4%), and AEs that led to permanent discontinuation of motesanib or placebo (32.7% v 14.2%) and P/C (37.8% v 25.5%) were higher in the motesanib plus P/C arm versus the placebo plus P/C arm (Table 3) .
Most common AEs in the motesanib plus P/C arm were decreased appetite (n = 116; 59.2%), diarrhea (n = 114; 58.2%), alopecia (n = 113; 57.7%), peripheral sensory neuropathy (n = 107; 54.6%), and nausea (n = 103; 52.6%) and in the placebo plus P/C arm, alopecia (n = 132; 64.7%), peripheral sensory neuropathy . The most common grade $ 3 AEs in the motesanib plus P/C arm were neutropenia (n = 51; 26.0%), decreased neutrophil count (n = 34; 17.3%), and hypertension (n = 32; 16.3%) and in the placebo plus P/ C arm, neutropenia (n = 53; 26.0%), decreased neutrophil count (n = 24; 11.8%), and leukopenia (n = 10; 4.9%). All-grade AEs and grade $ 3 AEs with at least a five-percentage-point difference in incidence rates between treatment arms are listed in Table 4 . The most common serious AEs in the motesanib plus P/C group were pneumonia (n = 13; 6.6%), decreased appetite (n = 8; 4.1%), cholecystitis (n = 7; 3.6%), and febrile neutropenia (n = 6; 3.1%) and in the placebo plus P/C arm, decreased appetite, pneumonia, pulmonary embolism, and pleural effusion (each n = 4; 2.0%). Thirteen AEs were fatal (eight in the motesanib plus P/C arm, five in the placebo plus P/C arm). Three deaths in the motesanib plus P/C arm as a result of congestive cardiac failure, interstitial lung disease, and peritonitis (each n = 1) were considered to be related to motesanib plus P/C. An additional death as a result of acute myocardial infarction and acute renal failure in the motesanib plus P/C arm was considered related to the P/C component of therapy.
DISCUSSION
In this phase III randomized, placebo-controlled, double-blind study, motesanib plus P/C did not significantly improve PFS versus placebo plus P/C in East Asian patients with stage IV/recurrent nonsquamous NSCLC. The findings are consistent with overall findings of the phase III MONET1 study 6 but do not replicate those of the subgroup analysis of Asian patients. 7 The results add to the body of evidence that suggests that in general (with the possible exception of the tyrosine kinase inhibitor [TKI] nintedanib and the monoclonal antibodies bevacizumab and ramucirumab, which have achieved small incremental increases in OS), [13] [14] [15] VEGF pathway inhibitors in combination with chemotherapy do not provide a significant clinical benefit to unselected (ie, in terms of biomarkers) patients with advanced nonsquamous NSCLC.
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The prognostic relevance of the baseline covariates for PFS was investigated and showed a treatment effect in patient subgroups defined by mutant-type EGFR, $ 5% weight loss, no prior adjuvant therapy, and prior radiation therapy (Fig 2B) . These subgroup analyses may offer an explanation for the differing results between our study and the MONET1 Asian subgroup analysis. A higher incidence of EGFR mutations has been reported in Asian Abbreviations: CR, complete response; DOR, duration of response; ORR, overall response rate; P/C, paclitaxel and carboplatin; PR, partial response; TTR, time to tumor response. *P , .001.
versus non-Asian patients with NSCLC. [8] [9] [10] EGFR mutations have been shown to be a good predictor of clinical benefit after treatment with EGFR TKIs, 17 and preclinical and clinical studies have suggested a synergistic effect with the combination of VEGF and EGFR inhibitors. 18 In the current study, most East Asian patients had wild-type or unknown-type EGFR status (79.3%); the EGFR mutant rate was substantially lower than that reported in the literature for Asian patients with NSCLC 19 possibly because these patients selected EGFR TKIs as first-line treatment. Although EGFR mutational status was not presented in the MONET1 Asian subgroup analysis, a higher number of Asian patients with EGFR mutations in the MONET1 study could have explained the differential activity observed versus in the current study. Finally, subgroup analyses can generate misleading results; therefore, although trials are adequately powered for their main end points, they may not be sufficiently powered to detect differences in efficacy between subgroups as a result of multiple comparisons.
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The current findings demonstrate this risk of failure when performing a confirmatory study designed on the basis of results from a subgroup analysis. Unless the prior subanalysis is statistically powered or associated with sufficient scientific rationale for biomarker data or tumor pathology that could explain the effects in a specific subset of patients, a risk exists that the prior results were mistakenly positive.
Motesanib plus P/C was associated with increased toxicity versus placebo plus P/C. The incidences of grade $ 3 AEs and AEs that led to permanent discontinuation of motesanib or placebo were higher in the motesanib plus P/C arm. AEs reported more frequently in the motesanib plus P/C arm were GI disorders (diarrhea, nausea, vomiting, abdominal pain); hypertension; and gallbladder related (cholecystitis, gallbladder enlargement, liver disorder), which were the main AEs that resulted in motesanib Abbreviations: AE, adverse event; P/C, paclitaxel and carboplatin. 24 (11.8) 10 (4.9) discontinuation. A low incidence of thromboembolic events was observed in both arms. These AEs generally were consistent with those observed in previous studies of motesanib 5, 6, 21 and other angiogenesis inhibitors in advanced NSCLC. [22] [23] [24] Differences in patient management versus that in the MONET1 study, such as the requirement for early treatment termination for gallbladder toxicities, may have affected the treatment period and led to reduced efficacy with motesanib plus P/C versus that in MONET1. The incidence of gallbladder-related AEs (cholecystitis, cholecystitis acute, gallbladder enlargement, gallbladder edema) in MONET1 was 8% in the motesanib plus P/C arm versus , 1% in the placebo arm, and in the Asian subanalysis of MONET1, this was 9% versus 2%, respectively. This disparity also is reflected in the current study, with 19% v 1% of patients reporting gallbladder-related AEs.
In summary, this phase III study in East Asian patients with stage IV/recurrent nonsquamous NSCLC demonstrates that treatment with motesanib plus P/C shows some hypothesis-generating efficacy signals in terms of ORR and DOR versus placebo plus P/C. However, the study did not show a significant improvement in the primary end point of PFS or the key secondary end point of OS.
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